NEW YORK, December 31, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting HCA Holdings, Inc. (NYSE: HCA), Opko Health, Inc. (NYSE: OPK), Santarus, Inc. (NASDAQ: SNTS), Coronado Biosciences, Inc. (NASDAQ: CNDO), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
HCA Holdings, Inc. Research Report
On December 18, 2013, HCA Holdings, Inc. (HCA Holdings) announced that it has agreed to purchase a site at Capitol View in the North Gulch area. The Company informed that its Parallon Business Solutions and Sarah Cannon Research Institute subsidiaries will relocate to this site. Richard M. Bracken, HCA's Chairman and CEO, said, "We appreciate Mayor Dean's continued support of our expansion in Davidson County, and we look forward to completing this project, which will promote the growth and development of the North Gulch area." The Full Research Report on HCA Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Opko Health, Inc. Research Report
On December 19, 2013, Opko Health, Inc. (Opko) announced the completion of patient recruitment for the second phase 3 trial of Rayaldy[TM] to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. Opko informed that the said trial is the second of two identical randomized, double-blind, placebo-controlled, multi-site studies intended to establish the safety and efficacy of Rayaldy[TM] as a new treatment for SHPT in the targeted population. The Company reported that top-line data from both trials are expected in mid-2014. The Full Research Report on Opko Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Santarus, Inc. Research Report
On December 23, 2013, Santarus, Inc. (Santarus) announced that it has started patient enrollment in a multicenter, multinational, randomized, double-blind, placebo-controlled, multiple ascending dose study with the investigational drug SAN-300. Santarus informed that SAN-300 is the Company's novel antibody that inhibits very late antigen-1 (VLA-1; α1β1 integrin). The Company plans to enroll approximately 90 patients in the study. "SAN-300 is a novel humanized monoclonal antibody that inhibits VLA-1, a cell adhesion molecule which plays a key role at sites of chronic inflammation," said Mark C. Totoritis, M.D., Senior Vice President of Clinical Research at Santarus. "We believe that SAN-300 has potential application as a drug candidate in multiple inflammatory and autoimmune diseases, including RA, inflammatory bowel disease, and psoriasis." The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Coronado Biosciences, Inc. Research Report
On December 20, 2013, Coronado Biosciences, Inc. (Coronado) announced the appointment of Dr. Lindsay A. Rosenwald as the Company's Chairman, President and CEO, effective December 19, 2013. The Company also announced the appointment of Mr. Michael S. Weiss as Director and Co-Vice Chairman of Coronado's Board of Directors. The Company further reported that Harlan F. Weisman, M.D., who has served as a director of Coronado since August 2012 will be departing the Company. "We thank Harlan on behalf of the Company for his efforts and leadership and wish him much success in his future endeavors," said Dr. Lindsay A. Rosenwald. The Full Research Report on Coronado Biosciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Idera Pharmaceuticals, Inc. Research Report
On December 26, 2013, Idera Pharmaceuticals, Inc. (Idera) stock rose 10.03% to end the day at $3.73, compared to the previous trading day's closing price of $3.39. The Company's stock rose 19.94% over the past three trading days, compared to the Dow Jones Industrial Average which rose 1.60% over the same trading period. The Full Research Report on Idera Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner